Adenocarcinoma News and Research

RSS

Adenocarcinoma is cancer that begins in cells that line certain internal organs and that have gland-like (secretory) properties.

Heartburn and cancer: an interview with Mindy Mintz Mordecai

What most of us think of as heartburn is a symptom of Reflux Disease or GERD (Gastroesophageal Reflux Disease). It’s that burning discomfort an individual experiences when stomach acids and other fluids come back up into their esophagus.

14 Aug 2012

Amgen announces decision to stop ganitumab Phase 3 trial in advanced pancreatic cancer

Amgen today announced a decision to stop the ganitumab (AMG 479) Phase 3 GAMMA (Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas) trial following the recommendation of an independent Data Monitoring Committee (DMC) overseeing the trial.

9 Aug 2012

VEGF inhibitor fails to improve nonsquamous NSCLC overall survival

Adding motesanib to carboplatin–paclitaxel does not boost overall survival in patients with advanced nonsquamous non-small-cell lung cancer, including those with adenocarcinoma, say MONET1 investigators.

8 Aug 2012

Lung cancer patients can be screened for ALK-inhibitor suitability

Anaplastic lymphoma kinase gene status in patients with lung adenocarcinoma can be determined non-invasively using circulating tumor cells, research shows.

8 Aug 2012

Interface zone fibroblasts play key role in gastric cancer

Interface zone fibroblasts in gastric adenocarcinoma promote the invasion, migration, and proliferation of cancer cells, as well as prevent apoptosis, to a greater degree than normal or tumor zone fibroblasts, say researchers.

8 Aug 2012

EPHA3 mutations may be important drivers of lung cancers

Vanderbilt-Ingram Cancer Center researchers have identified how one of the genes most commonly mutated in lung cancer may promote such tumors.

31 Jul 2012

CytRx commences aldoxorubicin plus doxorubicin Phase 1b trial in advanced solid tumors

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced the initiation of a Phase 1b clinical trial to determine the maximum tolerated dose and to evaluate preliminary efficacy of aldoxorubicin (formerly INNO-206) administered in combination with the commonly used chemotherapeutic agent doxorubicin in patients with advanced solid tumors who have failed other therapies.

26 Jul 2012

VEGF inhibitor fails to improve nonsquamous NSCLC overall survival

24 Jul 2012

Stromal cells offer chemotherapy clue in early lung cancer

Podoplanin-positive cancer-associated fibroblasts predict recurrence in stage I lung adenocarcinoma, which could help identify patients suited for adjuvant chemotherapy, research shows.

24 Jul 2012

Endoscopy, better tissue sampling required to improve care for patients with oesophageal cancer

The world's largest review of all the evidence on the best way of managing and treating common pre-cancerous and cancerous conditions of the oesophagus (gullet) has found that good endoscopy equipment, more endoscopic surgery, and more tissue sampling are required to improve care for patients.

24 Jul 2012

Bioniche receives U.S. and Canadian approval for first of two canine oncology products

Bioniche Life Sciences Inc., a research-based, technology-driven Canadian biopharmaceutical company, today announced that the first of two canine oncology products has received approval by regulators in both the U.S. and Canada.

24 Jul 2012

Antibody detects progenitor cells in cancers and cirrhosis of liver

The study, published in the journal Stem Cell, adds to our understanding of the role of stem and next stage progenitor cells in tissue regeneration and in the diagnosis and treatment of cancer.

21 Jul 2012

Tips to help minimize risks associated with acid reflux disease

While the overall death rates from several cancers such as breast and lung have gone down, there has been a meteoric rise in cases of esophageal cancer. Studies have shown that from 1975 to 2001, the incidence of esophageal adenocarcinoma rose approximately sixfold in the United States (from four to 23 cases per million), a relative increase greater than that for melanoma, breast, or prostate cancer.

17 Jul 2012

Prostate cancer treatment regrets linked to comorbidity

Men with cardiovascular disease are significantly more likely to regret their prostate cancer treatment choice than men without this comorbidity and have an increased risk for adverse effects, US researchers warn.

16 Jul 2012

Chemotherapy improves survival for patients with periampullary cancer following resection

Patients who had surgery for periampullary cancer (a variety of types of cancer that are located in and near the head of the pancreas, including an area called the ampulla where the bile duct joins up with the pancreatic duct to empty their secretions into the upper small intestine) and received chemotherapy had a statistically significant survival benefit, compared to patients who did not receive chemotherapy, after adjusting for prognostic variables, according to a study in the July 11 issue of JAMA.

11 Jul 2012

Prostate cancer patients with CVD are 52% more likely to regret their treatment choices

Prostate cancer patients with cardiovascular disease were 52 per cent more likely to regret their treatment choices than men without problems with their heart or veins, according to a study published in the July issue of the urology journal BJUI International.

3 Jul 2012

CytRx granted European patent for tumor-targeting linker platform technology

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that the European Patent Office (EPO) has issued a patent covering the Company's tumor-targeting linker platform technology and pharmaceutical compositions.

2 Jul 2012

New approach improves survival in patients with inoperable complex pancreatic adenocarcinoma

Investigators at the University of Texas MD Anderson Cancer Center, Houston, have reported on a new approach to treating previously inoperable complex pancreatic adenocarcinoma that has significantly increased long-term survival for some patients.

27 Jun 2012

CytRx achieves key milestone in advancing tamibarotene Phase 2b trial for NSCLC

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced the recommendation by the Data Safety Monitoring Board (DSMB) to continue with the global Phase 2b clinical trial with tamibarotene in combination with chemotherapeutical agents as a first-line treatment for patients with advanced non-small-cell lung cancer.

26 Jun 2012

TGen, Scottsdale Healthcare open INNO-206 Phase 2 trial for pancreatic cancer

An investigational drug that acts like a Trojan Horse to deliver cancer killing agents for pancreatic cancer is being studied at the Virginia G. Piper Cancer Center Clinical Trials, a partnership between Scottsdale Healthcare and the Translational Genomics Research Institute (TGen) that treats cancer patients with promising new drugs.

15 Jun 2012